📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Clean Max to Early Redeem ₹499 Crore Listed NCDs Using IPO Proceeds
Clean Max Enviro Energy Solutions has announced the early redemption of 4,990 listed Non-Convertible Debentures (NCDs) totaling ₹499 crore, scheduled for April 2, 2026. The company is utilizing proceeds from its Initial Public Offer (IPO) to facilitate this prepayment, alongside ₹100 crore in unlisted NCDs and a ₹400 crore facility from Tata Capital. Major institutional holders including Allianz Global Investors and Nomura will receive the principal plus accrued interest. This move indicates a strategic deleveraging of the balance sheet following its public listing.
Key Highlights
Early redemption of 4,990 listed, zero-coupon NCDs with a face value of ₹10 lakh each, totaling ₹499 crore.
Redemption date is set for April 2, 2026, with the record date fixed as per regulatory norms.
Funding for the redemption is sourced from the company's IPO proceeds as part of its debt management strategy.
Additional prepayments include ₹100 crore in unlisted NCDs and a ₹400 crore facility with Tata Capital Limited.
Major debenture holders involved include Allianz Global Investors, Nomura Capital, and IL&FS Infrastructure Debt Fund.
💼 Action for Investors
Investors should view this as a positive step toward strengthening the balance sheet and reducing future interest costs. Monitor the company's post-IPO financial statements for improvements in the debt-to-equity ratio.
Clean Science Q3 FY26 PAT Declines 13.6% YoY to ₹54.1 Cr; ₹2 Interim Dividend Declared
Clean Science and Technology Limited reported a consolidated revenue of ₹2,163.6 million for Q3 FY26, marking an 11.5% growth YoY but an 8.2% decline sequentially. Net profit for the quarter fell to ₹541.2 million, down from ₹626.4 million in the previous year, reflecting margin pressure. The company declared an interim dividend of ₹2 per share (200%) with a record date of February 5, 2026. The results indicate a challenging quarter with both YoY and QoQ profit contraction despite higher annual revenue.
Key Highlights
Consolidated Revenue from operations stood at ₹2,163.6 million, up 11.5% YoY but down 8.2% QoQ.
Consolidated Net Profit (PAT) decreased by 13.6% YoY to ₹541.2 million.
Interim Dividend of ₹2 per equity share (200% of face value) declared for FY 2025-26.
Basic EPS for the quarter fell to ₹5.09 from ₹5.90 in the corresponding quarter of the previous year.
Total expenses for the quarter were ₹1,438.2 million, showing significant pressure on operating margins compared to the previous year.
💼 Action for Investors
Investors should be cautious due to the sequential and year-on-year decline in profitability and margin compression. Monitor management commentary regarding raw material costs and demand outlook in the specialty chemicals segment.
Clean Science Q3 FY26: Revenue Declines 21% Y-o-Y Amid Pricing Pressure; HALS Business Grows 55%
Clean Science reported a challenging Q3 FY26 with consolidated revenue declining 10% sequentially to INR 216 crores and a 21% Y-o-Y drop in sales. The performance was hit by pricing pressure from Chinese competitors in the MEHQ segment and the loss of a key FMCG customer for 4-MAP due to backward integration. However, the HALS business showed strong momentum with 55% Y-o-Y growth and achieved EBITDA breakeven in its subsidiary, Clean Fino Chem. The company also commercialized its new hydroquinone and catechol plant in December, which is expected to improve margins for downstream products like TBHQ.
Key Highlights
Consolidated revenue moderated by 10% Q-o-Q to INR 216 crores with PAT margins at 21% and EBITDA at INR 72 crores.
HALS business delivered robust 55% Y-o-Y growth and achieved EBITDA breakeven in the subsidiary Clean Fino Chem Limited.
9-month revenue declined 10% Y-o-Y to INR 602 crores, attributed to pricing pressure and lower offtake in the Agchem segment.
Commercialized hydroquinone and catechol plant in Dec 2025; Performance Chemical 2 capex on track for Q1 FY27.
Board approved an interim dividend of INR 2 per share and welcomed two new independent directors.
💼 Action for Investors
Investors should monitor the ramp-up of the HALS segment and the margin recovery from the new hydroquinone plant to offset pricing pressures in core products. While the HALS breakeven is positive, the loss of a key FMCG customer and Chinese competition remain significant near-term headwinds.
Clean Science Declares ₹2 Interim Dividend; Q3 Revenue Grows 12% YoY to ₹218.5 Cr
Clean Science and Technology reported a 12.2% YoY growth in consolidated revenue from operations, reaching ₹2,185.5 million for Q3 FY26. However, consolidated net profit saw a decline of approximately 11% YoY, coming in at ₹459.3 million compared to ₹516.1 million in the same quarter last year. The Board has declared an interim dividend of ₹2 per share (200% of face value) with a record date of February 6, 2026. The decline in profit despite revenue growth suggests pressure on margins or increased operational costs during the period.
Key Highlights
Consolidated Revenue from Operations grew 12.2% YoY to ₹2,185.5 million in Q3 FY26.
Consolidated Net Profit decreased by 11% YoY to ₹459.3 million from ₹516.1 million.
Declared an interim dividend of ₹2 per equity share (200% on face value of ₹1).
Record date for dividend eligibility is February 6, 2026, with payment by February 23, 2026.
Consolidated EPS for the quarter declined to ₹4.32 from ₹4.86 in the year-ago period.
💼 Action for Investors
Investors should monitor the margin compression as net profit fell despite double-digit revenue growth. While the dividend provides a yield, the bottom-line performance suggests rising input or operational costs that need further investigation.
Clean Science Declares ₹2 Interim Dividend; Q3 PAT Declines to ₹45.8 Crore
Clean Science and Technology has announced an interim dividend of ₹2 per share (200% of face value) for FY 2025-26, with the record date set for February 6, 2026. The company's consolidated revenue for Q3 FY26 stood at ₹249.6 crore, showing growth over the ₹194.7 crore reported in the same quarter last year. However, net profit saw a decline to ₹45.8 crore from ₹56.7 crore YoY and ₹65.7 crore sequentially. The dividend payment is scheduled to be completed by February 23, 2026.
Key Highlights
Interim dividend of ₹2 per equity share of face value ₹1 each
Consolidated Revenue from operations at ₹2,496.4 million for Q3 FY26
Consolidated Net Profit (PAT) fell to ₹458.3 million vs ₹567.5 million YoY
Basic EPS for the quarter decreased to ₹4.32 from ₹5.35 YoY
Record date for dividend eligibility is February 6, 2026
💼 Action for Investors
Investors seeking the dividend must hold shares before the February 6 record date. While the dividend is a positive payout, the sequential and year-on-year decline in profitability suggests monitoring margin pressures in the specialty chemicals segment.
Clean Science Q3 FY26: Revenue Falls 9% YoY; Interim Dividend of ₹2 Declared
Clean Science and Technology reported a weak Q3 FY26 with consolidated revenue declining 9% YoY to ₹219 crore and PAT dropping 30% YoY to ₹46 crore. EBITDA margins faced significant pressure, contracting to 33.4% from 41.5% in the year-ago period. Despite the slowdown, the company commercialized new capacities for Hydroquinone and Catechol and declared an interim dividend of ₹2 per share. The Performance Chemicals segment now contributes 76% of total revenue, driven by growth in the HALS series.
Key Highlights
Consolidated Q3 FY26 Revenue at ₹219 crore, down 9% YoY and 11% QoQ.
Consolidated PAT for the quarter stood at ₹46 crore, a 30% decline compared to Q3 FY25.
EBITDA margins compressed to 33.4% in Q3 FY26 from 41.5% in Q3 FY25 and 36.4% in Q2 FY26.
Incurred ₹165 crore capex in 9M FY26, primarily for the Clean Fino Chem Ltd (CFCL) subsidiary.
Successfully commercialized Hydroquinone and Catechol capacities during Q3 FY26.
💼 Action for Investors
Investors should exercise caution as profitability margins have significantly compressed despite new product launches. Monitor the utilization rates of the newly commercialized Hydroquinone and Catechol plants for signs of recovery in the coming quarters.
Clean Science Declares ₹2 Interim Dividend; Q3 Net Profit Rises 25.5% YoY to ₹45.8 Cr
Clean Science and Technology reported a robust performance for Q3 FY2025-26, with consolidated revenue growing 28.2% YoY to ₹249.6 crore. Net profit for the quarter increased by 25.5% to ₹45.8 crore, up from ₹36.5 crore in the previous year. Alongside the earnings, the board declared an interim dividend of ₹2 per share (200% of face value). The company maintains a healthy balance sheet with an EPS improvement to ₹4.32 for the quarter.
Key Highlights
Declared interim dividend of ₹2 per equity share (200%) with a record date of February 6, 2026
Consolidated Revenue from operations rose 28.2% YoY to ₹2,496.14 million
Consolidated Net Profit (PAT) increased 25.5% YoY to ₹458.41 million
Basic and Diluted EPS improved to ₹4.32 from ₹3.44 in the corresponding quarter last year
Nine-month consolidated PAT stands at ₹1,211.12 million on a revenue of ₹6,769.30 million
💼 Action for Investors
The combination of double-digit growth and a steady dividend payout reflects strong operational efficiency. Investors should hold for long-term gains while monitoring the record date of February 6 for dividend eligibility.
Clean Science Q3 FY26 Results: Consolidated Revenue Up 28%, Declares ₹2 Interim Dividend
Clean Science and Technology reported a 28% year-on-year growth in consolidated revenue from operations, reaching ₹2,496.44 million for Q3 FY26. However, consolidated net profit declined significantly to ₹458.41 million from ₹633.29 million in the previous year's corresponding quarter, indicating margin pressure. On a standalone basis, the company maintained stability with a net profit of ₹651.25 million. To reward shareholders, the board declared an interim dividend of ₹2 per share (200% of face value) with a record date of February 6, 2026.
Key Highlights
Consolidated Revenue from Operations rose 28% YoY to ₹2,496.44 million in Q3 FY26.
Consolidated Net Profit fell to ₹458.41 million compared to ₹633.29 million in Q3 FY25.
Declared an interim dividend of ₹2 per equity share (200%) for the financial year 2025-26.
Standalone Net Profit remained steady at ₹651.25 million versus ₹630.48 million YoY.
The record date for dividend eligibility is February 6, 2026, with payment scheduled by February 23, 2026.
💼 Action for Investors
Investors should investigate the cause of the sharp decline in consolidated profit despite strong revenue growth, focusing on subsidiary performance and raw material costs. While the dividend is positive, the margin compression warrants a cautious approach until cost-efficiency improves.
Clean Science Invests ₹50 Crore in Subsidiary Clean Fino-Chem for Project Funding
Clean Science and Technology Limited (CSTL) has invested ₹50 crore in its wholly-owned subsidiary, Clean Fino-Chem Limited (CFCL), via a rights issue. The investment involved subscribing to 8,36,121 equity shares at a price of ₹598 per share (including a ₹588 premium). CFCL is a specialty chemicals manufacturer that has shown rapid growth, with turnover increasing from ₹1.92 crore in FY24 to ₹46.77 crore in FY25. This capital infusion is specifically earmarked to fund ongoing projects, indicating a focus on capacity expansion.
Key Highlights
Investment of ₹50.00 crore in wholly-owned subsidiary Clean Fino-Chem Limited.
Acquisition of 8,36,121 equity shares at ₹598 per share (₹10 face value + ₹588 premium).
CFCL turnover grew significantly from ₹1.92 crore in FY24 to ₹46.77 crore in FY25.
Capital will be utilized primarily for funding specialty chemical projects within the subsidiary.
💼 Action for Investors
Investors should monitor the execution of CFCL's projects as the subsidiary is scaling rapidly and becoming a meaningful contributor to consolidated revenue. The continued investment signals management's confidence in the specialty chemicals growth pipeline.
Clean Science Subsidiary Commences Commercial Production of Hydroquinone and Catechol
Clean Science and Technology's wholly-owned subsidiary, Clean Fino-Chem Limited, has officially started commercial production of Hydroquinone (HQ) and Catechol as of December 18, 2025. This expansion positions the company as a significant domestic manufacturer, aiming to capture market share through import substitution. The production of HQ is strategically designed to create cross-selling opportunities with existing MEHQ customers and enhance the company's TBHQ market presence. Furthermore, Catechol will be used for captive consumption in the manufacturing of Guaiacol and Veratrole, improving vertical integration.
Key Highlights
Commenced commercial production of Hydroquinone and Catechol on December 18, 2025
Aims to become a key domestic manufacturer to drive import substitution in specialty chemicals
HQ production creates cross-selling opportunities with MEHQ customers and strengthens TBHQ market share
Catechol will be captively consumed for the production of Guaiacol and Veratrole
Project highlights robust in-house R&D and synergistic project engineering capabilities
💼 Action for Investors
Investors should view this as a significant growth milestone that enhances vertical integration and market reach. Monitor the revenue contribution from these new lines in the upcoming quarterly results to assess the speed of market penetration.
Clean Science Shareholders Approve MD Succession and New Board Appointments
Clean Science and Technology Limited has received shareholder approval for a significant leadership transition effective April 1, 2026. Mr. Siddhartha Ashok Sikchi will be elevated to Managing Director for a five-year term, while the current MD, Mr. Ashok Ramnarayan Boob, will transition to Executive Vice Chairman. Additionally, shareholders approved the appointment and re-appointment of four Independent Directors, ensuring board stability. All resolutions were passed with overwhelming majorities, often exceeding 99% of the votes cast, indicating strong institutional and promoter support.
Key Highlights
Mr. Siddhartha Ashok Sikchi appointed as Managing Director for a 5-year term starting April 1, 2026.
Current MD Mr. Ashok Ramnarayan Boob to transition to Executive Vice Chairman from April 2026 to July 2027.
Mr. Keval Navinchandra Doshi re-appointed as Independent Director for 5 years with 99.46% favorable votes.
New Independent Directors Mr. Raj Kamal and Ms. Pallavi Gokhale appointed for 5-year terms starting November 2025.
All six resolutions passed with requisite majority via postal ballot involving 2,49,493 members.
💼 Action for Investors
Investors should view the structured succession plan and board strengthening as a positive indicator of corporate governance and long-term stability. No immediate action is required as the transition is well-planned for 2026.